Data is not available at this time.
Doximity, Inc. operates a leading digital platform for medical professionals, offering a suite of tools designed to streamline communication, collaboration, and workflow efficiency in the healthcare sector. The company generates revenue primarily through subscription-based services, advertising, and premium offerings tailored to physicians, nurses, and other healthcare providers. Its platform serves as a critical hub for professional networking, telehealth solutions, and clinical decision support, positioning Doximity as a key enabler of digital transformation in healthcare. The company has established a strong market position by leveraging its extensive network of verified medical professionals, which enhances engagement and retention. Unlike general social networks, Doximity’s focus on healthcare-specific needs—such as secure messaging, e-faxing, and referral management—creates high switching costs and deepens user reliance. This specialization allows the company to command premium pricing and maintain a competitive moat against broader tech entrants. Doximity’s growth is further supported by secular trends like telehealth adoption and regulatory tailwinds favoring digital health solutions.
Doximity reported revenue of $570.4 million for FY 2025, with net income of $223.2 million, reflecting a robust net margin of approximately 39%. The company’s operating cash flow of $273.3 million underscores strong cash generation capabilities, while negligible capital expenditures highlight capital-light operations. These metrics indicate high operational efficiency and scalability inherent in its software-driven model.
The company’s diluted EPS of $1.11 demonstrates its ability to translate top-line growth into shareholder returns. With no significant capital expenditures, Doximity’s free cash flow closely aligns with operating cash flow, emphasizing capital efficiency. This positions the company to reinvest in product development or pursue strategic acquisitions without straining its balance sheet.
Doximity maintains a solid financial position, with $209.6 million in cash and equivalents against minimal total debt of $12.4 million. The negligible leverage and strong liquidity provide flexibility to navigate market fluctuations or fund growth initiatives. The absence of dividends suggests a focus on retaining earnings for reinvestment or share repurchases.
Doximity’s revenue and profitability trends reflect sustained demand for its platform, though specific growth rates are undisclosed. The company does not currently pay dividends, opting instead to prioritize organic growth and potential M&A. Its capital-light model and high margins support future scalability without requiring significant external financing.
The market likely values Doximity on its premium profitability metrics and growth potential in digital health. Its P/E ratio and other valuation multiples would hinge on expectations for sustained adoption of telehealth and workflow tools, though comparable benchmarks are unavailable without further data.
Doximity’s network effects, healthcare specialization, and scalable platform provide durable competitive advantages. The outlook remains positive, driven by industry digitization tailwinds, though regulatory changes or competition could pose risks. The company’s financial health positions it well to capitalize on emerging opportunities in the healthcare technology space.
Company filings (CIK: 0001516513), estimated FY 2025 data
show cash flow forecast
Fiscal year | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | 2050 | |
INCOME STATEMENT | ||||||||||||||||||||||||||
Revenue growth rate, % | NaN | |||||||||||||||||||||||||
Revenue, $ | NaN | |||||||||||||||||||||||||
Variable operating expenses, $m | NaN | |||||||||||||||||||||||||
Fixed operating expenses, $m | NaN | |||||||||||||||||||||||||
Total operating expenses, $m | NaN | |||||||||||||||||||||||||
Operating income, $m | NaN | |||||||||||||||||||||||||
EBITDA, $m | NaN | |||||||||||||||||||||||||
Interest expense (income), $m | NaN | |||||||||||||||||||||||||
Earnings before tax, $m | NaN | |||||||||||||||||||||||||
Tax expense, $m | NaN | |||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
BALANCE SHEET | ||||||||||||||||||||||||||
Cash and short-term investments, $m | NaN | |||||||||||||||||||||||||
Total assets, $m | NaN | |||||||||||||||||||||||||
Adjusted assets (=assets-cash), $m | NaN | |||||||||||||||||||||||||
Average production assets, $m | NaN | |||||||||||||||||||||||||
Working capital, $m | NaN | |||||||||||||||||||||||||
Total debt, $m | NaN | |||||||||||||||||||||||||
Total liabilities, $m | NaN | |||||||||||||||||||||||||
Total equity, $m | NaN | |||||||||||||||||||||||||
Debt-to-equity ratio | NaN | |||||||||||||||||||||||||
Adjusted equity ratio | NaN | |||||||||||||||||||||||||
CASH FLOW | ||||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
Depreciation, amort., depletion, $m | NaN | |||||||||||||||||||||||||
Funds from operations, $m | NaN | |||||||||||||||||||||||||
Change in working capital, $m | NaN | |||||||||||||||||||||||||
Cash from operations, $m | NaN | |||||||||||||||||||||||||
Maintenance CAPEX, $m | NaN | |||||||||||||||||||||||||
New CAPEX, $m | NaN | |||||||||||||||||||||||||
Total CAPEX, $m | NaN | |||||||||||||||||||||||||
Free cash flow, $m | NaN | |||||||||||||||||||||||||
Issuance/(repurchase) of shares, $m | NaN | |||||||||||||||||||||||||
Retained Cash Flow, $m | NaN | |||||||||||||||||||||||||
Pot'l extraordinary dividend, $m | NaN | |||||||||||||||||||||||||
Cash available for distribution, $m | NaN | |||||||||||||||||||||||||
Discount rate, % | NaN | |||||||||||||||||||||||||
PV of cash for distribution, $m | NaN | |||||||||||||||||||||||||
Current shareholders' claim on cash, % | NaN |